BioMarin to acquire Amicus Therapeutics for $4.8 billion in rare disease bet  (2025-12-19)
BioMarin Pharmaceutical said on ⁠Friday it would acquire Amicus ‍Therapeutics ‍for about $4.8 ‍billion, expanding its presence in rare metabolic diseases.